Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGES2 | Q9H7Z7 | 8/20 | 0.49 |
| ▸ | CA9 | Q16790 | 4/20 | 0.47 |
| ▸ | CA12 | O43570 | 4/20 | 0.47 |
| ▸ | CA2 | P00918 | 4/20 | 0.47 |
| ▸ | CA1 | P00915 | 3/20 | 0.47 |
| ▸ | PKM | P14618 | 1/20 | 0.47 |
| ▸ | SOS1 | Q07889 | 1/20 | 0.47 |
| ▸ | CA3 | P07451 | 1/20 | 0.44 |
| ▸ | CA6 | P23280 | 1/20 | 0.44 |
| ▸ | CA5A | P35218 | 1/20 | 0.44 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.44 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.44 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | CA7 | P43166 | 1/20 | 0.41 |
| ▸ | CA13 | Q8N1Q1 | 1/20 | 0.41 |
| ▸ | TET2 | Q6N021 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29721599 | 1.00 | PTGES2 (0.49) | PTGES2CA9CA12CA2CA1 | |
| Hydrochloric Acid SCHEMBL1554456 | 0.98 | PTGES2 (0.47) | PTGES2CA9CA12CA2CA1 | |
| Hydrochloric Acid SCHEMBL30646289 | 0.98 | PTGES2 (0.47) | PTGES2CA9CA12CA2CA1 | |
| SCHEMBL28119649 | 0.94 | PTGES2 (0.45) | PTGES2CA9CA12CA2CA1 | |
| SCHEMBL29556118 | 0.86 | PTGS1 (0.48) | PTGES2CA9CA12CA2CA1 | |
| SCHEMBL789994 | 0.86 | PTGS1 (0.48) | PTGES2CA9CA12CA2CA1 | |
| Trifluoroacetic Acid SCHEMBL28810548 | 0.86 | CA9 (0.40) | PTGES2CA9CA12CA2CA1 | |
| Hydrochloric Acid SCHEMBL29968814 | 0.84 | PTGS1 (0.47) | PTGES2CA9CA12CA2CA1 | |
| Iodide SCHEMBL28547721 | 0.84 | PTGS1 (0.47) | PTGES2CA9CA12CA2CA1 | |
| SCHEMBL1645034 | 0.80 | CA1 (0.47) | PTGES2CA9CA12CA2CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 87 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024115549-A1 | ARYL- AND HETEROARYL-SULFONAMIDE DERIVATIVES AS CCR8 MODULATORS | IDORSIA PHARMACEUTICALS LTD (CH) | 2024-06-06 | — | — | WO | claimed |
| CN-114746419-A | N- (3- (5- (pyrimidin-4-yl) thiazol-4-yl) phenyl) sulfonamide compounds and their use as BRAF inhibitors | 国家医疗保健研究所 | 2022-07-12 | — | — | CN | claimed |
| US-20220153734-A1 | Pyrazolopyridine Compounds For IRE1 Inhibition | Optikira, LLC | 2022-05-19 | — | — | US | claimed |
| CN-108963389-B | Gelable system for lithium-air battery and preparation method and application thereof | 北京师范大学 | 2020-11-13 | — | — | CN | claimed |
| EP-3637524-A1 | GELATINIZED SYSTEM AND APPLICATIONS IN LITHIUM AIR BATTERY, SUPER CAPACITOR OR CAPACITOR BATTERY IN ORGANIC SYSTEM | Beijing Normal University (CN) | 2020-04-15 | — | — | EP | claimed |
| EP-3637525-A1 | FLEXIBLE ALL-SOLID-STATE LITHIUM-ION SECONDARY BATTERY AND MANUFACTURING METHOD THEREFOR | Beijing Normal University (CN) | 2020-04-15 | — | — | EP | claimed |
| US-20200099097-A1 | GELABLE SYSTEM AND USES THEREOF IN LITHIUM-AIR BATTERIES, ORGANIC SUPERCAPACITORS OR CAPACITOR BATTERIES | BEIJING NORMAL UNIVERSITY (CN) | 2020-03-26 | — | — | US | claimed |
| US-20200099090-A1 | FLEXIBLE ALL-SOLID-STATE LITHIUM-ION SECONDARY BATTERY AND PREPARATION METHOD THEREOF | BEIJING NORMAL UNIVERSITY (CN) | 2020-03-26 | — | — | US | claimed |
| CN-109761944-A | A kind of chrysin amide derivatives and preparation method thereof and medical usage | 武汉翼博济生生物科技有限公司 | 2019-05-17 | — | — | CN | claimed |
| CN-108963389-A | It is a kind of for lithium-air battery can gelling system and its preparation method and application | 北京师范大学 | 2018-12-07 | — | — | CN | claimed |
| EP-2678336-A1 | THIAZOLYLPHENYL-BENZENESULFONAMIDO DERIVATIVES AS KINASE INHIBITORS | Nerviano Medical Sciences S.r.l. (IT) | 2014-01-01 | — | — | EP | claimed |
| WO-2012113774-A1 | THIAZOLYLPHENYL-BENZENESULFONAMIDO DERIVATIVES AS KINASE INHIBITORS | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2012-08-30 | — | — | WO | claimed |
| JP-2007511596-A | — | — | 2007-05-10 | — | — | JP | claimed |
| EP-1687309-A1 | PYRROLOPYRIMIDINE COMPOUNDS USEFUL IN TREATMENT OF CANCER | Pfizer Products Inc. (US) | 2006-08-09 | — | — | EP | claimed |
| WO-2005047289-A1 | PYRROLOPYRIMIDINE COMPOUNDS USEFUL IN TREATMENT OF CANCER | PFIZER PRODUCTS INC. (US) | 2005-05-26 | — | — | WO | claimed |
| US-20260116910-A1 | POLYCYCLIC COMPOUNDS AND METHODS THEREOF | HEPAITECH BEIJING BIOPHARMA TECH CO LTD (CN) | 2026-04-30 | — | — | US | disclosed |
| WO-2026044398-A1 | SALTS OF 5-CHLORO-2-FLUORO-N-(2-FLUORO-4-(3-METHYL-4-[(1-METHYLPIPERIDIN-4-YL)OXY]-1H-PYRAZOLO[3,4-D]PYRIMIDIN-6-YL)PHENYL)BENZENE SULFONAMIDE AND CRYSTALLINE FORMS THEREOF | THRYV THERAPEUTICS INC. (CA) | 2026-03-05 | — | — | WO | disclosed |
| EP-1392643-A2 | TRISUBSTITUTED-N- (1S)-1,2,3,4-TETRAHYDRO-1-NAPHTHALENYL] BENZAMIDES WHICH INHIBIT P2X3 AND P2X2/3 CONTAINING RECEPTORS | Abbott Laboratories (US) | 2004-03-03 | — | — | EP | disclosed |
| US-20030083359-A1 | Trisubstituted-N-[(1S)-1,2,3,4-terrahydro-1-naphthalenyl]benzamides which inhibit P2X2/3 containing receptors | ABBVIE INC. | 2003-05-01 | — | — | US | disclosed |
| WO-2002094767-A2 | TRISUBSTITUTED-N-[(1S)-1,2,3,4-TETRAHYDRO-1-NAPHTHALENYL] BENZAMIDES WHICH INHIBIT P2X3 AND P2X2/3 CONTAINING RECEPTORS | ABBOTT LABORATORIES (US) | 2002-11-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030083359-A1 | Trisubstituted-N-[(1S)-1,2,3,4-terrahydro-1-naphthalenyl]benzamides which inhibit P2X2/3 containing receptors | P2RX3, P2RX1, P2RX2 | PTGES2 321/4885CA9 1628/4885CA12 4169/4885 |
| US-20260116910-A1 | POLYCYCLIC COMPOUNDS AND METHODS THEREOF | NR1H3, NR1H2, CPT1A | PTGES2 543/4885CA9 1140/4885CA12 972/4885 |
| US-20220153734-A1 | Pyrazolopyridine Compounds For IRE1 Inhibition | XBP1, ERN1, ERN2 | PTGES2 2154/4885CA9 4484/4885CA12 4841/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.